Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Maze Therapeutics, Inc.NASDAQ: MAZE
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$26.55M, compared with -$35.4M a year earlier. Trailing-twelve-month operating income was -$134.05M.
Context
- Operating income increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 10 analysts of -$109.05M (+23.7%) for the fiscal year ending Dec 2026, a step up from the -348.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$26.55M+30.2% QoQ
- Last fiscal yearDec 2025
- -$142.9M-348.1% YoY
- LTMMar 2026
- -$134.05M-367.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +25.0% | -17.1% | -42.1 pp |
| 1 year | -348.1% | +23.7% | +371.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (142.9M) USD
- Year-over-year change
- -348.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (142.9M) | -348.1% |
| FY2024 | 2024-12-31 | 57.59M | +158.4% |
| FY2023 | 2023-12-31 | (98.55M) | +11.2% |
| FY2022 | 2022-12-31 | (111.03M) | — |
Operating Income vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -367.0% is the lowest of 8, against a peer median of -26.3%.
- Operating income amounts to 670.3% of revenue for MAZE, versus a peer median of 48.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $116.26M USD | -83.8% | — | 11.5% | |
| LTM Mar 2026 | -$36.74M USD | -26.3% | — | — | |
| LTM Mar 2026 | -$37.42M USD | +5.6% | — | 8.7% | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$73.39M USD | +4.7% | — | 76.2% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | -$101.71M USD | -24.3% | — | 985.9% |
| FY2025 | -€130.95M EUR | -34.2% | — | 2921.0% | |
| LTM Sep 2026 | -$133.49M USD | -46.5% | — | 20.5% | |
| LTM Mar 2026 | -$134.05M USD | -367.0% | — | 670.3% | |
| Peer median (excluding MAZE) | — | -26.3% | — | 48.4% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 2.4M |
| Gross Profit | 0 | 0 | 167.5M | (2.4M) |
| Gross Margin | — | — | 100.0% | — |
| Research & Development | 88.19M | 73.95M | 83.5M | 108.45M |
| Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M |
| Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M |
| EBITDA | (111.12M) | (96.33M) | 56.7M | (128.72M) |
| EBITDA Margin | — | — | 33.9% | — |
| Operating Income | (111.03M) | (98.55M) | 57.59M | (142.9M) |
| Operating Margin | — | — | 34.4% | — |
| Interest Income | 2.03M | 1.97M | 4.65M | 11.78M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.91M) | (1.86M) | (4.18M) | 11.78M |
| Income Before Tax | (114.94M) | (100.42M) | 53.4M | (131.12M) |
| Pre-Tax Margin | — | — | 31.9% | — |
| Income Tax Expense | 0 | 0 | 1.17M | 0 |
| Net Income | (114.94M) | (100.42M) | 52.23M | (131.12M) |
| Net Margin | — | — | 31.2% | — |
| EPS (Basic) | (2.63) | (2.29) | 0.08 | (3.05) |
| EPS (Diluted) | (2.63) | (2.29) | 0.08 | (3.05) |
| Weighted Avg Shares | 43.78M | 43.78M | 43.8M | 42.98M |
| Weighted Avg Shares (Diluted) | 43.78M | 43.78M | 43.8M | 42.98M |
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.